Table 3.
Copy number alterations and mRNA expression of advanced soft tissue sarcoma cases with pazopanib treatment
| Case number | Pazopanib response | Copy number alteration | Quantitative-PCR and/or CNA of GLI1 |
| 1 (CR) | CR | CDK4 AMP, GLI1 AMP | Very high |
| 2 | Long SD | PDGFRA AMP (2.69), 12q13-14 (CDK4 AMP (3.66), MDM2 AMP (5.74)) |
Very high |
| 3 | Long SD | No copy number alteration | Low |
| 4 | Long SD | No copy number alteration | Low |
| 5 | PD | EGFR AMP (2.01) | Low |
| 6 | PD | PDGFRA AMP (6.40), KIT AMP (5.28) | Low |
CR = complete response; PD = progressive disease; long SD (long-term SD) = SD over 6 months;
AMP = amplification; CNA = copy number alteration.